186 related articles for article (PubMed ID: 9616140)
1. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose.
Römer W; Hanauske AR; Ziegler S; Thödtmann R; Weber W; Fuchs C; Enne W; Herz M; Nerl C; Garbrecht M; Schwaiger M
Blood; 1998 Jun; 91(12):4464-71. PubMed ID: 9616140
[TBL] [Abstract][Full Text] [Related]
2. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma.
Torizuka T; Nakamura F; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Kobayashi M; Ouchi Y
Eur J Nucl Med Mol Imaging; 2004 Jan; 31(1):22-8. PubMed ID: 14574514
[TBL] [Abstract][Full Text] [Related]
3. Decreased 18F-FDG uptake 1 day after initiation of chemotherapy for malignant lymphomas.
Yamane T; Daimaru O; Ito S; Yoshiya K; Nagata T; Ito S; Uchida H
J Nucl Med; 2004 Nov; 45(11):1838-42. PubMed ID: 15534052
[TBL] [Abstract][Full Text] [Related]
4. [FDG-PET on the day after first chemotherapy in malignant lymphoma].
Yamane T; Daimaru O; Itoh S; Nagata T; Yoshiya K; Itoh S; Uchida H; Shinai T; Imai T; Ohishi H
Nihon Igaku Hoshasen Gakkai Zasshi; 2002 Dec; 62(14):839-42. PubMed ID: 12607955
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
Spaepen K; Stroobants S; Dupont P; Van Steenweghen S; Thomas J; Vandenberghe P; Vanuytsel L; Bormans G; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
J Clin Oncol; 2001 Jan; 19(2):414-9. PubMed ID: 11208833
[TBL] [Abstract][Full Text] [Related]
6. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.
Kostakoglu L; Coleman M; Leonard JP; Kuji I; Zoe H; Goldsmith SJ
J Nucl Med; 2002 Aug; 43(8):1018-27. PubMed ID: 12163626
[TBL] [Abstract][Full Text] [Related]
7. Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma.
Spaepen K; Stroobants S; Dupont P; Vandenberghe P; Thomas J; de Groot T; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
Ann Oncol; 2002 Sep; 13(9):1356-63. PubMed ID: 12196360
[TBL] [Abstract][Full Text] [Related]
8. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma.
Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
Haematologica; 2000 Jun; 85(6):613-8. PubMed ID: 10870118
[TBL] [Abstract][Full Text] [Related]
9. Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET?
Reinhardt MJ; Herkel C; Altehoefer C; Finke J; Moser E
Ann Oncol; 2005 Sep; 16(9):1524-9. PubMed ID: 15946979
[TBL] [Abstract][Full Text] [Related]
10. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.
Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
Blood; 1999 Jul; 94(2):429-33. PubMed ID: 10397709
[TBL] [Abstract][Full Text] [Related]
11. Evidence for a cardiac metabolic switch in patients with Hodgkin's lymphoma.
Heckmann MB; Totakhel B; Finke D; Anker MS; Müller-Tidow C; Haberkorn U; Katus HA; Lehmann LH
ESC Heart Fail; 2019 Aug; 6(4):824-829. PubMed ID: 31278857
[TBL] [Abstract][Full Text] [Related]
12. Early response assessment using 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma.
Herrmann K; Wieder HA; Buck AK; Schöffel M; Krause BJ; Fend F; Schuster T; Meyer zum Büschenfelde C; Wester HJ; Duyster J; Peschel C; Schwaiger M; Dechow T
Clin Cancer Res; 2007 Jun; 13(12):3552-8. PubMed ID: 17575218
[TBL] [Abstract][Full Text] [Related]
13. Dynamic and static approaches to quantifying 18F-FDG uptake for measuring cancer response to therapy, including the effect of granulocyte CSF.
Doot RK; Dunnwald LK; Schubert EK; Muzi M; Peterson LM; Kinahan PE; Kurland BF; Mankoff DA
J Nucl Med; 2007 Jun; 48(6):920-5. PubMed ID: 17504870
[TBL] [Abstract][Full Text] [Related]
14. Lymphomatous involvement of gastrointestinal tract: evaluation by positron emission tomography with (18)F-fluorodeoxyglucose.
Phongkitkarun S; Varavithya V; Kazama T; Faria SC; Mar MV; Podoloff DA; Macapinlac HA
World J Gastroenterol; 2005 Dec; 11(46):7284-9. PubMed ID: 16437629
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
Qiao W; Zhao J; Wang C; Wang T; Xing Y
Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658
[TBL] [Abstract][Full Text] [Related]
16. Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma.
Cremerius U; Fabry U; Wildberger JE; Zimny M; Reinartz P; Nowak B; Schaefer W; Buell U; Osieka R
Bone Marrow Transplant; 2002 Jul; 30(2):103-11. PubMed ID: 12132049
[TBL] [Abstract][Full Text] [Related]
17. Value of [18F]fluorodeoxyglucose-positron emission tomography in managing patients with aggressive non-Hodgkin's lymphoma.
Meignan M; Haioun C; Itti E; Rahmouni A; Reyes F
Clin Lymphoma Myeloma; 2006 Jan; 6(4):306-13. PubMed ID: 16507208
[TBL] [Abstract][Full Text] [Related]
18. Role of 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients.
Gennari A; Donati S; Salvadori B; Giorgetti A; Salvadori PA; Sorace O; Puccini G; Pisani P; Poli M; Dani D; Landucci E; Mariani G; Conte PF
Clin Breast Cancer; 2000 Jul; 1(2):156-61; discussion 162-3. PubMed ID: 11899654
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic evaluation and prognostic value of interim hybrid PET/CT with (18)F-FDG after three to four cycles of chemotherapy in non-Hodgkin's lymphoma.
Zhao J; Qiao W; Wang C; Wang T; Xing Y
Hematology; 2007 Oct; 12(5):423-30. PubMed ID: 17852456
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of lesions of malignant lymphoma using histograms of regional SUV].
Ito S; Yamane T; Yoshiya K; Nagata T; Uchida H; Daimaru O; Kato K; Nishida K; Hashimoto H
Kaku Igaku; 2003 May; 40(2):175-84. PubMed ID: 12884784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
